CY1124051T1 - Θεραπεια νευρολογικων διαταραχων - Google Patents
Θεραπεια νευρολογικων διαταραχωνInfo
- Publication number
- CY1124051T1 CY1124051T1 CY20211100267T CY211100267T CY1124051T1 CY 1124051 T1 CY1124051 T1 CY 1124051T1 CY 20211100267 T CY20211100267 T CY 20211100267T CY 211100267 T CY211100267 T CY 211100267T CY 1124051 T1 CY1124051 T1 CY 1124051T1
- Authority
- CY
- Cyprus
- Prior art keywords
- formula
- optionally substituted
- alkyl
- treatment
- morpholinyl
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- -1 tautomers Substances 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μία ένωση του τύπου (Ι), όπου τα Χ1, Χ2 και Χ3 είναι, ανεξάρτητα το ένα από το άλλο, Ν ή CH· με την προϋπόθεση ότι τουλάχιστον δύο από τα Χ1, Χ2 και Χ3 είναι Ν· το Υ είναι Ν ή CH· τα R1 και R2 είναι ανεξάρτητα το ένα από το άλλο (iii) ένα μορφολινύλιο του τύπου (II) όπου το βέλος δηλώνει τον δεσμό στον τύπο (I)· και όπου τα R3 και R4 είναι ανεξάρτητα το ένα από το άλλο Η, C1-C3αλκύλιο ενδεχομένως υποκατεστημένο με ένα ή δύο ΟΗ, C1-C2φθοροαλκύλιο, C1-C2αλκοξυ, C1-C2αλκοξυC1-C3αλκύλιο, CN, ή C(Ο)Ο-C1-C2αλκύλιο· ή τα R3 και R4 σχηματίζουν μαζί ένα δισθενές υπόλοιπο -R5R6- που επιλέγεται από C1-C3αλκυλένιο, ενδεχομένως υποκατεστημένο με 1 έως 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, ή οποιαδήποτε από τις δομές όπου τα βέλη δηλώνουν τους δεσμούς στον τύπο (II)· ή (iv) ένας κορεσμένος 6-μελής ετεροκυκλικός δακτύλιος Ζ που επιλέγεται από θειομορφολινύλιο και πιπεραζινύλιο, ενδεχομένως υποκατεστημένο με 1 έως 3 R7· όπου το R7 είναι ανεξάρτητα σε κάθε εμφάνιση C1-C3αλκύλιο ενδεχομένως υποκατεστημένο με ένα ή δύο ΟΗ, C1-C2φθοροαλκύλιο, C1-C2αλκοξυC1-C3αλκύλιο, C3-C6κυκλοαλκύλιο· ή δύο R7 υποκαταστάτες σχηματίζουν μαζί ένα δισθενές υπόλοιπο -R8R9-που επιλέγεται από C1-C3αλκυλένιο ενδεχομένως υποκατεστημένο με 1 έως 4 F, -CH2-O-CH2- ή -Ο-CH2CH2-O-· με την προϋπόθεση ότι τουλάχιστον ένα από τα R1 και R2 είναι ένα μορφολινύλιο του τύπου II· και προφάρμα, μεταβολίτες, ταυτομερή, επιδιαλυτώματα και φαρμακευτικά αποδεκτά άλατα αυτής, για χρήση στην πρόληψη ή θεραπεία μιας νευρολογικής διαταραχής σε ένα υποκείμενο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16170107 | 2016-05-18 | ||
| PCT/EP2017/025136 WO2017198346A1 (en) | 2016-05-18 | 2017-05-17 | Treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124051T1 true CY1124051T1 (el) | 2022-05-27 |
Family
ID=56024138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100267T CY1124051T1 (el) | 2016-05-18 | 2021-03-26 | Θεραπεια νευρολογικων διαταραχων |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20190284178A1 (el) |
| EP (1) | EP3458067B1 (el) |
| JP (1) | JP6991158B2 (el) |
| KR (1) | KR102472461B1 (el) |
| CN (1) | CN109475560B (el) |
| AU (1) | AU2017265383B2 (el) |
| BR (1) | BR112018073579A8 (el) |
| CA (1) | CA3022753A1 (el) |
| CY (1) | CY1124051T1 (el) |
| DK (1) | DK3458067T3 (el) |
| ES (1) | ES2863250T3 (el) |
| HR (1) | HRP20210477T1 (el) |
| HU (1) | HUE053494T2 (el) |
| IL (1) | IL263080B (el) |
| LT (1) | LT3458067T (el) |
| MX (1) | MX2018014168A (el) |
| PL (1) | PL3458067T3 (el) |
| PT (1) | PT3458067T (el) |
| RS (1) | RS61655B1 (el) |
| RU (1) | RU2765868C2 (el) |
| SG (1) | SG11201809792TA (el) |
| SI (1) | SI3458067T1 (el) |
| TW (1) | TWI753912B (el) |
| WO (1) | WO2017198346A1 (el) |
| ZA (1) | ZA201807393B (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102483630B1 (ko) | 2016-05-18 | 2023-01-02 | 토르쿠르 아게 | 피부 병변의 치료 |
| RU2020115351A (ru) * | 2017-11-23 | 2021-12-23 | Пикур Терапьютикс Аг | Лечение кожных заболеваний |
| BR112023020804A2 (pt) * | 2021-04-09 | 2023-12-19 | Univ Basel | Derivado de triazina como inibidores covalentes reversíveis e irreversíveis de pi3k |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CA2838399C (en) * | 2006-02-09 | 2017-03-07 | Alba Therapeutics Corporation | Formulations for a tight junction effector |
| JP5546240B2 (ja) * | 2006-04-26 | 2014-07-09 | ジェネンテック， インコーポレイテッド | 医薬化合物 |
| PL2050749T3 (pl) | 2006-08-08 | 2018-03-30 | Chugai Seiyaku Kabushiki Kaisha | Pochodna pirymidyny jako inhibitor pi3k i jej zastosowanie |
| JP2010518107A (ja) * | 2007-02-06 | 2010-05-27 | ノバルティス アーゲー | Ｐｉ３−キナーゼ阻害剤およびその使用方法 |
| NZ588526A (en) | 2008-05-23 | 2012-08-31 | Wyeth Llc | Triazine compounds as pi3 kinase and mtor inhibitors |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| SG11201602602RA (en) | 2013-10-04 | 2016-04-28 | Univ Basel | Conformationally restricted pi3k and mtor inhibitors |
| MA40933A (fr) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| WO2017198347A1 (en) | 2016-05-18 | 2017-11-23 | Piqur Therapeutics Ag | Treatment of skin lesions |
| KR102483630B1 (ko) * | 2016-05-18 | 2023-01-02 | 토르쿠르 아게 | 피부 병변의 치료 |
-
2017
- 2017-05-17 LT LTEP17725862.1T patent/LT3458067T/lt unknown
- 2017-05-17 HU HUE17725862A patent/HUE053494T2/hu unknown
- 2017-05-17 EP EP17725862.1A patent/EP3458067B1/en active Active
- 2017-05-17 RU RU2018140013A patent/RU2765868C2/ru not_active Application Discontinuation
- 2017-05-17 PT PT177258621T patent/PT3458067T/pt unknown
- 2017-05-17 PL PL17725862T patent/PL3458067T3/pl unknown
- 2017-05-17 WO PCT/EP2017/025136 patent/WO2017198346A1/en unknown
- 2017-05-17 SG SG11201809792TA patent/SG11201809792TA/en unknown
- 2017-05-17 CA CA3022753A patent/CA3022753A1/en active Pending
- 2017-05-17 JP JP2018560457A patent/JP6991158B2/ja active Active
- 2017-05-17 ES ES17725862T patent/ES2863250T3/es active Active
- 2017-05-17 CN CN201780029954.7A patent/CN109475560B/zh active Active
- 2017-05-17 DK DK17725862.1T patent/DK3458067T3/da active
- 2017-05-17 RS RS20210393A patent/RS61655B1/sr unknown
- 2017-05-17 SI SI201730696T patent/SI3458067T1/sl unknown
- 2017-05-17 MX MX2018014168A patent/MX2018014168A/es unknown
- 2017-05-17 BR BR112018073579A patent/BR112018073579A8/pt active Search and Examination
- 2017-05-17 AU AU2017265383A patent/AU2017265383B2/en active Active
- 2017-05-17 KR KR1020187035896A patent/KR102472461B1/ko active IP Right Grant
- 2017-05-17 US US16/301,729 patent/US20190284178A1/en not_active Abandoned
- 2017-05-18 TW TW106116465A patent/TWI753912B/zh active
-
2018
- 2018-11-05 ZA ZA2018/07393A patent/ZA201807393B/en unknown
- 2018-11-18 IL IL263080A patent/IL263080B/en unknown
-
2020
- 2020-12-17 US US17/125,012 patent/US11878972B2/en active Active
-
2021
- 2021-03-22 HR HRP20210477TT patent/HRP20210477T1/hr unknown
- 2021-03-26 CY CY20211100267T patent/CY1124051T1/el unknown
-
2023
- 2023-12-01 US US18/526,732 patent/US20240343718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124051T1 (el) | Θεραπεια νευρολογικων διαταραχων | |
| CL2022001513A1 (es) | Inhibidores de kras g12c | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CY1126106T1 (el) | Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης | |
| CY1123025T1 (el) | Αναστολεις βρωμοεπικρατειας | |
| CY1122521T1 (el) | ΕΝΩΣΗ (6S,9AS)-N-BENZYΛO-6-((4-YΔPOΞYΦAINYΛO)ΜΕΘΥΛΟ)-4,7-ΔΙΟΞΟ-8-((6-(3-(ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΑΖΕΤΙΔΙΝΟ-1-ΥΛΟ)ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΜΕΘΥΛΟ)-2-(ΠΡΟΠ-2-ΕΝ-1-ΥΛΟ)-OKTAΫΔPO-lH-ΠYPAZINO(2,l-C)(l,2,4)ΤΡΙΑΖΙΝΟ-1-ΚΑΡΒΟΞΑΜΙΔΙΟΥ | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| CY1124795T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια και προφυλαξη λοιμωξεων χειρουργικης θεσης | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| CY1124908T1 (el) | Παραγωγο μορφινανης | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| CY1121564T1 (el) | Σπειρο-ινδολινες για τη θεραπεια και την προφυλαξη απο τη λοιμωξη απο τον αναπνευστικο συγκυτιακο ιο (rsv) | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| TR201900680T4 (tr) | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. | |
| CY1123864T1 (el) | Νεα παραγωγα αμινο-ιμιδαζοπυριδινης σαν αναστολεις κινασης janus και φαρμακευτικες χρησεις | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina |